Abstract 180P
Background
Circadian rhythms (CRs) are crucial biological processes that influence various physiological functions in humans. Previous studies from our team have shown that chronic circadian disruption, specifically chronic jetlag (CJL), increases tumor burden in a mouse melanoma model. The tumor immune microenvironment plays a complex regulatory role in tumorigenesis. However, the specific immune cell functions regulated by circadian disruption to promote tumor progression remain largely undefined. This study aims to demonstrate the critical role of NK cells in the innate immune system during circadian disruption across various mouse models.
Methods
We utilized three distinct mouse models representing varying immune states: C57BL/6 mice, NOD-SCID mice (lacking T/B cells), and B-NDG mice (lacking T/B/NK cells), melanomas were inoculated subcutaneously. Light was manipulated to modulate the circadian clock. Mice were maintained under normal light-dark environment (LD) or CJL environment (6-hour advance of the LD12:12 cycle every 2 days). We use RNA-seq, flow cytometry and quantitative immunofluorescence to analysis tumor immune microenvironment.
Results
Our findings indicate that tumor growth rates significantly increased under CJL in C57 and NOD-SCID mice compared to normal light-dark schedules. In contrast, the tumor growth rate difference between the two rhythm patterns disappeared in NK-cell-deficient B-NDG mice. Flow cytometry analysis revealed that in C57 mice, CJL led to an increase in CD8+ T cells and a decrease in NK cells in tumors, with similar trends observed in the spleen. Additionally, RNA-seq data indicated that CJL inhibits pathways related to both innate and adaptive immunity in tumors, significantly downregulating NK cell function pathways.
Conclusions
These data demonstrate that chronic circadian disruption promotes tumor progression by altering the tumor immune microenvironment, with changes in NK cell quantity and function playing a pivotal role in CJL's effects on tumor growth.
Legal entity responsible for the study
West China Hospital, Sichuan University.
Funding
Sichuan Science and Technology Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract